Biotech Values

[jq1234]

Pazdur still needs to make sure it works.

I am a big supporter of IMGN, and IMGN is my long term portofolio. However, I have to say, even though this 137-patient randomized trial data raise the chance of phase III (OS primary endpoint) success, there is no guarantee it will. Avastin in MBC was a good example. If Roche simply withdraw Avastin from MBC indication, it may very well bode well for other oncology drugs seeking accelerated approval.